102 related articles for article (PubMed ID: 16946586)
1. [Pharmacokinetic study of cancer chemotherapy].
Itoh T
Yakugaku Zasshi; 2006 Sep; 126(9):723-35. PubMed ID: 16946586
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
3. Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue.
Itagaki S; Sumi Y; Shimamoto S; Itoh T; Hirano T; Takemoto I; Iseki K
Cancer Chemother Pharmacol; 2005 May; 55(5):502-6. PubMed ID: 15711827
[TBL] [Abstract][Full Text] [Related]
4. Involvement of specific transport system on uptake of lactone form of SN-38 in human intestinal epithelial cell line Caco-2.
Ueno Y; Matsuda H; Mizutani H; Iwamoto T; Okuda M
Biol Pharm Bull; 2012; 35(1):54-8. PubMed ID: 22223337
[TBL] [Abstract][Full Text] [Related]
5. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
6. Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2.
Itoh T; Itagaki S; Sumi Y; Hirano T; Takemoto I; Iseki K
Cancer Chemother Pharmacol; 2005 May; 55(5):420-4. PubMed ID: 15565324
[TBL] [Abstract][Full Text] [Related]
7. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
[TBL] [Abstract][Full Text] [Related]
8. Characterization of secretory intestinal transport of the lactone form of CPT-11.
Takemoto I; Itagaki S; Chiba M; Itoh T; Hirano T; Iseki K
Cancer Chemother Pharmacol; 2006 Jan; 57(1):129-33. PubMed ID: 16003561
[TBL] [Abstract][Full Text] [Related]
9. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
Sugiyama Y; Kato Y; Chu X
Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
[TBL] [Abstract][Full Text] [Related]
10. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
Fujita D; Saito Y; Nakanishi T; Tamai I
Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
[TBL] [Abstract][Full Text] [Related]
11. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
[TBL] [Abstract][Full Text] [Related]
12. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
Chu XY; Kato Y; Ueda K; Suzuki H; Niinuma K; Tyson CA; Weizer V; Dabbs JE; Froehlich R; Green CE; Sugiyama Y
Cancer Res; 1998 Nov; 58(22):5137-43. PubMed ID: 9823324
[TBL] [Abstract][Full Text] [Related]
13. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
[TBL] [Abstract][Full Text] [Related]
14. Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.
Arimori K; Kuroki N; Kumamoto A; Tanoue N; Nakano M; Kumazawa E; Tohgo A; Kikuchi M
Pharm Res; 2001 Jun; 18(6):814-22. PubMed ID: 11474786
[TBL] [Abstract][Full Text] [Related]
15. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.
Horikawa M; Kato Y; Sugiyama Y
Pharm Res; 2002 Sep; 19(9):1345-53. PubMed ID: 12403072
[TBL] [Abstract][Full Text] [Related]
16. [Intestinal absorption and secretion mechanism of carboxylate drugs].
Itagaki S
Yakugaku Zasshi; 2009 Nov; 129(11):1341-9. PubMed ID: 19881206
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.
Bansal T; Awasthi A; Jaggi M; Khar RK; Talegaonkar S
Life Sci; 2008 Aug; 83(7-8):250-9. PubMed ID: 18619980
[TBL] [Abstract][Full Text] [Related]
19. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
Kaneda N; Hosokawa Y; Yokokura T; Awazu S
Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
[TBL] [Abstract][Full Text] [Related]
20. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]